Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors
The clinical efficacy and durability of KRAS<sup>G12C</sup>-targeted therapies are limited by the development of resistance mechanisms. Here, we provide a review of recent KRAS<sup>G12C</sup>-targeted therapy and immunotherapy-unifying strategies that utilize covalently modif...
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Journal article |
| Giella: | English |
| Almmustuhtton: |
Cell Press
2023
|
| _version_ | 1826312511718162432 |
|---|---|
| author | Abdel Mouti, M Pauklin, S |
| author_facet | Abdel Mouti, M Pauklin, S |
| author_sort | Abdel Mouti, M |
| collection | OXFORD |
| description | The clinical efficacy and durability of KRAS<sup>G12C</sup>-targeted therapies are limited by the development of resistance mechanisms. Here, we provide a review of recent KRAS<sup>G12C</sup>-targeted therapy and immunotherapy-unifying strategies that utilize covalently modified peptide/MHC class I complexes as tumor-specific neoantigens to tag drug-resistant cancer cells for destruction with hapten-based immunotherapeutics. |
| first_indexed | 2024-03-07T08:08:57Z |
| format | Journal article |
| id | oxford-uuid:ffa9f480-4b63-43f3-bc7d-b29c7f051cc8 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-04-09T03:55:41Z |
| publishDate | 2023 |
| publisher | Cell Press |
| record_format | dspace |
| spelling | oxford-uuid:ffa9f480-4b63-43f3-bc7d-b29c7f051cc82024-03-08T12:53:41ZChemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumorsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ffa9f480-4b63-43f3-bc7d-b29c7f051cc8EnglishSymplectic ElementsCell Press2023Abdel Mouti, MPauklin, SThe clinical efficacy and durability of KRAS<sup>G12C</sup>-targeted therapies are limited by the development of resistance mechanisms. Here, we provide a review of recent KRAS<sup>G12C</sup>-targeted therapy and immunotherapy-unifying strategies that utilize covalently modified peptide/MHC class I complexes as tumor-specific neoantigens to tag drug-resistant cancer cells for destruction with hapten-based immunotherapeutics. |
| spellingShingle | Abdel Mouti, M Pauklin, S Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors |
| title | Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors |
| title_full | Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors |
| title_fullStr | Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors |
| title_full_unstemmed | Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors |
| title_short | Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors |
| title_sort | chemically modified neoantigen based immunotherapy for targeting krasg12c driven tumors |
| work_keys_str_mv | AT abdelmoutim chemicallymodifiedneoantigenbasedimmunotherapyfortargetingkrasg12cdriventumors AT pauklins chemicallymodifiedneoantigenbasedimmunotherapyfortargetingkrasg12cdriventumors |